The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways

Cancer and Metastasis Reviews

Volumn 27, Issue 2, 2008, Pages 123-135

  Lu, Xiongbin ^a,b   Nguyen, Thuy Ai ^a   Moon, Sung Hwan ^a   Darlington, Yolanda ^a   Sommer, Matthias ^a   Donehower, Lawrence A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ATM; p53; PP2C; PPM1D; Serine threonine phosphatase; Wip1

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE 2C; PROTEIN; TUMOR SUPPRESSOR PROTEIN; WILD TYPE P53 INDUCED PHOSPHATASE 1;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CARCINOGENICITY; DNA DAMAGE; FIBROBLAST; HOMEOSTASIS; HUMAN; NONHUMAN; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN TARGETING; REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENE PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; SIGNAL TRANSDUCTION;

EID: 43049128122     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-008-9127-x     Document Type: Review

References (75)

1. Abraham, R. T. (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes & Development, 15, 2177-2196.
2. Shiloh, Y. (2003). ATM and related protein kinases: safeguarding genome integrity. Nature Reviews Cancer, 3, 155-168.
3. Kim, S. T., Lim, D. S., Canman, C. E., & Kastan, M. B. (1999). Substrate specificities and identification of putative substrates of ATM kinase family members. Journal of Biological Chemistry, 274, 37538-37543.
4. Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald 3rd, E. R., Hurov, K. E., Luo, J., et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science, 316, 1160-1166.
5. Gorgoulis, V. G., Vassiliou, L. V., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature, 434, 907-913.
6. Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434, 864-870.
7. Shreeram, S., Demidov, O. N., Hee, W. K., Yamaguchi, H., Onishi, N., Kek, C., et al. (2006). Wip1 phosphatase modulates ATM-dependent signaling pathways. Molecular Cell, 23, 757-764.
8. Lu, X., Ma, O., Nguyen, T. A., Jones, S. N., Oren, M., & Donehower, L. A. (2007). The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell, 12, 342-354.
9. Fujimoto, H., Onishi, N., Kato, N., Takekawa, M., Xu, X. Z., Kosugi, A., et al. (2006). Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death and Differentiation, 13, 1170-1180.
10. Lu, X., Nannenga, B., & Donehower, L. A. (2005). PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes & Development, 19, 1162-1174.
11. Takekawa, M., Adachi, M., Nakahata, A., Nakayama, I., Itoh, F., Tsukuda, H., et al. (2000). p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO Journal, 19, 6517-6526.
12. Bulavin, D. V., Phillips, C., Nannenga, B., Timofeev, O., Donehower, L. A., Anderson, C. W., et al. (2004). Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nature Genetics, 36, 343-350.
13. Fiscella, M., Zhang, H., Fan, S., Sakaguchi, K., Shen, S., Mercer, W. E., et al. (1997). Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 94, 6048-6053.
14. Yoda, A., Xu, X. Z., Onishi, N., Toyoshima, K., Fujimoto, H., Kato, N., et al. (2006). Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. Journal of Biological Chemistry, 281, 24847-24862.
15. Yamaguchi, H., Minopoli, G., Demidov, O. N., Chatterjee, D. K., Anderson, C. W., Durell, S. R., et al. (2005). Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. Biochemistry, 44, 5285-5294.
16. Choi, J., Appella, E., & Donehower, L. A. (2000). The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. Genomics, 64, 298-306.
17. Bulavin, D. V., Demidov, O. N., Saito, S., Kauraniemi, P., Phillips, C., Amundson, S. A., et al. (2002). Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genetics, 31, 210-215.
18. Barford, D., Das, A. K., & Egloff, M. P. (1998). The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annual Review of Biophysics and Biomolecular Structure, 27, 133-164.
19. Moorhead, G. B., Trinkle-Mulcahy, L., & Ulke-Lemee, A. (2007). Emerging roles of nuclear protein phosphatases. Nature Reviews Molecular Cell Biology, 8, 234-244.
20. Barford, D. (1996). Molecular mechanisms of the protein serine/threonine phosphatases. Trends in Biochemical Sciences, 21, 407-412.
21. Jackson, M. D., & Denu, J. M. (2001). Molecular reactions of protein phosphatases-insights from structure and chemistry. Chemical Reviews, 101, 2313-2340.
22. Takekawa, M., Maeda, T., & Saito, H. (1998). Protein phosphatase 2Calpha inhibits the human stress-responsive p38 and JNK MAPK pathways. EMBO Journal, 17, 4744-4752.
23. Hanada, M., Kobayashi, T., Ohnishi, M., Ikeda, S., Wang, H., Katsura, K., et al. (1998). Selective suppression of stress-activated protein kinase pathway by protein phosphatase 2C in mammalian cells. FEBS Letters, 437, 172-176.
24. Yamaguchi, H., Durell, S. R., Feng, H., Bai, Y., Anderson, C. W., & Appella, E. (2006). Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Biochemistry, 45, 13193-13202.
25. Lu, X., Bocangel, D., Nannenga, B., Yamaguchi, H., Appella, E., & Donehower, L. A. (2004). The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Molecular Cell, 15, 621-634.
26. Lu, X., Nguyen, T. A., & Donehower, L. A. (2005). Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle, 4, 1060-1064.
27. Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., & Kastan, M. B. (1997). DNA damage induces phosphorylation of the amino terminus of p53. Genes & Development, 11, 3471-3481.
28. Bulavin, D. V., Saito, S., Hollander, M. C., Sakaguchi, K., Anderson, C. W., Appella, E., et al. (1999). Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO Journal, 18, 6845-6854.
29. Liu, Q., Guntuku, S., Cui, X. S., Matsuoka, S., Cortez, D., Tamai, K., et al. (2000). Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes & Development, 14, 1448-1459.
30. Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000). The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes & Development, 14, 289-300.
31. Maya, R., Balass, M., Kim, S. T., Shkedy, D., Leal, J. F., Shifman, O., et al. (2001). ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes & Development, 15, 1067-1077.
32. Derijard, B., Raingeaud, J., Barrett, T., Wu, I. H., Han, J., Ulevitch, R. J., et al. (1995). Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science, 267, 682-685.
33. Raingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J., et al. (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. Journal of Biological Chemistry, 270, 7420-7426.
34. She, Q. B., Chen, N., & Dong, Z. (2000). ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. Journal of Biological Chemistry, 275, 20444-20449.
35. Huang, C., Ma, W. Y., Maxiner, A., Sun, Y., & Dong, Z. (1999). p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. Journal of Biological Chemistry, 274, 12229-12235.
36. Krokan, H. E., Drablos, F., & Slupphaug, G. (2002). Uracil in DNA-occurrence, consequences and repair. Oncogene, 21, 8935-8948.
37. Rual, J. F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., et al. (2005). Towards a proteome-scale map of the human protein-protein interaction network. Nature, 437, 1173-1178.
38. Lu, X., Nguyen, T. A., Appella, E., & Donehower, L. A. (2004). Homeostatic regulation of base excision repair by a p53-induced phosphatase: Linking stress response pathways with DNA repair proteins. Cell Cycle, 3, 1363-1366.
39. Bartek, J., & Lukas, J. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, 421-429.
40. Zhao, H., & Piwnica-Worms, H. (2001). ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Molecular Cell Biology, 21, 4129-4139.
41. Karlsson-Rosenthal, C., & Millar, J. B. (2006). Cdc25: mechanisms of checkpoint inhibition and recovery. Trends in Cell Biology, 16, 285-292.
42. Melchionna, R., Chen, X. B., Blasina, A., & McGowan, C. H. (2000). Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nature Cell Biology, 2, 762-765.
43. Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., & Elledge, S. J. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proceedings of the National Academy of Sciences of the United States of America, 97, 10389-10394.
44. Ahn, J. Y., Schwarz, J. K., Piwnica-Worms, H., & Canman, C. E. (2000). Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Research, 60, 5934-5936.
45. Gatei, M., Sloper, K., Sorensen, C., Syljuasen, R., Falck, J., Hobson, K., et al. (2003). Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. Journal of Biological Chemistry, 278, 14806-14811.
46. Hirao, A., Cheung, A., Duncan, G., Girard, P. M., Elia, A. J., Wakeham, A., et al. (2002). Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Molecular Cell Biology, 22, 6521-6532.
47. Cuadrado, M., Martinez-Pastor, B., & Fernandez-Capetillo, O. (2006). "ATR activation in response to ionizing radiation: still ATM territory". Cell Division, 1, 7.
48. Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C., Lukas, J., et al. (2006). ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nature Cell Biology, 8, 37-45.
49. Nannenga, B., Lu, X., Dumble, M., Van Maanen, M., Nguyen, T. A., Sutton, R., et al. (2006). Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Molecular Carcinogenesis, 45, 594-604.
50. Oliva-Trastoy, M., Berthonaud, V., Chevalier, A., Ducrot, C., Marsolier-Kergoat, M. C., Mann, C., et al. (2007). The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene, 26, 1449-1458.
51. Fuku, T., Semba, S., Yutori, H., & Yokozaki, H. (2007). Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathology International, 57, 566-571.
52. Horn, H. F., & Vousden, K. H. (2007). Coping with stress: Multiple ways to activate p53. Oncogene, 26, 1306-1316.
53. Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P., & Harris, C. C. (2004). TP53 mutation spectra and load: A tool for generating hypotheses on the etiology of cancer. IARC Scientific Publications, 157, 247-270.
54. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery Jr., C. A., Butel, J. S., et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
55. Bond, G. L., Hu, W., & Levine, A. J. (2005). MDM2 is a central node in the p53 pathway: 12 years and counting. Current Cancer Drug Targets, 5, 3-8.
56. Shieh, S. Y., Ikeda, M., Taya, Y., & Prives, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91, 325-334.
57. Shreeram, S., Hee, W. K., Demidov, O. N., Kek, C., Yamaguchi, H., Fornace Jr., A. J., et al. (2006). Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. Journal of Experimental Medicine, 203, 2793-2799.
58. Ostman, A., Hellberg, C., & Bohmer, F. D. (2006). Protein-tyrosine phosphatases and cancer. Nature Reviews Cancer, 6, 307-320.
59. Arroyo, J. D., & Hahn, W. C. (2005). Involvement of PP2A in viral and cellular transformation. Oncogene, 24, 7746-7755.
60. Li, J., Yang, Y., Peng, Y., Austin, R. J., van Eyndhoven, W. G., Nguyen, K. C., et al. (2002). Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nature Genetics, 31, 133-134.
61. Momand, J., Jung, D., Wilczynski, S., & Niland, J. (1998). The MDM2 gene amplification database. Nucleic Acids Research, 26, 3453-3459.
62. Rauta, J., Alarmo, E. L., Kauraniemi, P., Karhu, R., Kuukasjarvi, T., & Kallioniemi, A. (2006). The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Research and Treatment, 95, 257-263.
63. Yu, E., Ahn, Y. S., Jang, S. J., Kim, M. J., Yoon, H. S., Gong, G., et al. (2007). Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Research and Treatment, 101, 269-278.
64. Hirasawa, A., Saito-Ohara, F., Inoue, J., Aoki, D., Susumu, N., Yokoyama, T., et al. (2003). Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clinical Cancer Research, 9, 1995-2004.
65. Saito-Ohara, F., Imoto, I., Inoue, J., Hosoi, H., Nakagawara, A., Sugimoto, T., et al. (2003). PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Research, 63, 1876-1883.
66. Loukopoulos, P., Shibata, T., Katoh, H., Kokubu, A., Sakamoto, M., Yamazaki, K., et al. (2007). Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome. Cancer Science, 98, 392-400.
67. Ehrbrecht, A., Muller, U., Wolter, M., Hoischen, A., Koch, A., Radlwimmer, B., et al. (2006). Comprehensive genomic analysis of desmoplastic medulloblastomas: Identification of novel amplified genes and separate evaluation of the different histological components. Journal of Pathology, 208, 554-563.
68. Mendrzyk, F., Radlwimmer, B., Joos, S., Kokocinski, F., Benner, A., Stange, D. E., et al. (2005). Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. Journal of Clinical Oncology, 23, 8853-8862.
69. Castellino, C., De Bortoli, M., Moon S. H., Lu, X., Skapura, D. G., Lin, L. L., et al. (2007). Medulloblastomas overexpress the p53-Inactivating oncogene Wip1/PPM1D. J. Neuro-Onc. (in press).
70. Demidov, O. N., Kek, C., Shreeram, S., Timofeev, O., Fornace, A. J., Appella, E., et al. (2007). The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene, 26, 2502-2506.
71. Choi, J., Nannenga, B., Demidov, O. N., Bulavin, D. V., Cooney, A., Brayton, C., et al. (2002). Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Molecular Cell Biology, 22, 1094-1105.
72. Belova, G. I., Demidov, O. N., Fornace Jr., A. J., & Bulavin, D. V. (2005). Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biology and Therapy, 4, 1154-1158.
73. Rayter, S., Elliott, R., Travers, J., Rowlands, M. G., Richardson, T. B., Boxall, K., et al. (2007). A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene (in press).
74. Proia, D. A., Nannenga, B. W., Donehower, L. A., & Weigel, N. L. (2006). Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. Journal of Biological Chemistry, 281, 7089-7101.
75. Schito, M. L., Demidov, O. N., Saito, S., Ashwell, J. D., & Appella, E. (2006). Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation. Journal of Immunology, 176, 4818-4825.